Results 161 to 170 of about 754,363 (313)
Amoxicillin-Induced Drug-Induced Liver Injury Superimposed on Acute Hepatitis C Infection in a Patient With Hurler Syndrome: A Diagnostic Challenge Assessed by the Updated RUCAM. [PDF]
Case Reports HepatolGarg A +6 more
europepmc +1 more source
Putting viral hepatitis on the map [PDF]
The DVH-funded FOA PS08-801 was intended to integrate primary and secondary viral hepatitis prevention services, education and counseling into health care settings and programs that serve adults at risk for viral hepatitis.
core
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Arthritis &Rheumatology, Accepted Article.Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz +13 more
wiley +1 more source
Hepatology, EarlyView., 2022 Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran +17 more
wiley +1 more source
Hepatitis B: Are You At Risk? (Chinese)
Learn more about information for people at risk for hepatitis B ...
core +1 more source
The Danish Database for Hepatitis B and C (DANHEP): A Nationwide, Prospective, Ongoing Cohort Study. [PDF]
Clin EpidemiolBollerup S +25 more
europepmc +1 more source
Hepatitis C: information about testing [PDF]
"Most people with Hepatitis C do not have any symptoms and do not know they are infected. As a result people could be living with Hepatitis C and appear healthy while liver damage silently occurs. If you think you might have been exposed to the Hepatitis
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.) Division of Viral Hepatitis.
core
British Journal of Clinical Pharmacology, EarlyView.Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
Hepatology, EarlyView., 2022 Graphical abstract summarizing the study design, main results and key findings Abstract Background and Aims Fatty liver disease (FLD) has been associated with excess mortality. Screening for hepatic steatosis (HS) in patients with metabolic dysfunction is therefore recommended by several guidelines, despite a paucity of evidence on the clinical ...
Laurens A. van Kleef +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim Clinically, interstitial lung disease (ILD) is a heterogeneous group of respiratory disorders. Due to their low incidence, pharmacovigilance database analysis is useful to detect them. Precise diagnosis is challenging as well as coding in these databases. Query criteria are among the key elements for a good signal detection.
Romane Freppel +4 more
wiley +1 more source